Net Income for Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's current net income (TTM) is $313.75M USD. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingNet IncomeSwitch metric
TTM (last 4 quarters)
$313.75M
YoY change
-212.8%
5Y CAGR
N/A
Peak year (2025)
$313.75M
Cumulative net income
-$7.04B
Net Income history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Net Income history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| Fiscal year | Period ended | Reported | Net Income | YoY |
|---|---|---|---|---|
| 2025 | $313.75M | -212.8% | ||
| 2024 | -$278.16M | -36.8% | ||
| 2023 | -$440.24M | -61.1% | ||
| 2022 | -$1.13B | +32.6% | ||
| 2021 | -$852.82M | -0.6% | ||
| 2020 | -$858.28M | -3.1% | ||
| 2019 | -$886.12M | +16.4% | ||
| 2018 | -$761.50M | +55.1% | ||
| 2017 | -$490.87M | +19.7% | ||
| 2016 | -$410.11M | +41.4% | ||
| 2015 | -$290.07M | -19.5% | ||
| 2014 | -$360.39M | +303.9% | ||
| 2013 | -$89.22M | -15.8% | ||
| 2012 | -$106.01M | +83.9% | ||
| 2011 | -$57.65M | +32.5% | ||
| 2010 | -$43.52M | -8.6% | ||
| 2009 | -$47.59M | +81.3% | ||
| 2008 | -$26.25M | -69.3% | ||
| 2007 | -$85.47M | +147.0% | ||
| 2006 | -$34.61M | -19.4% | ||
| 2005 | -$42.91M | +31.4% | ||
| 2004 | -$32.65M | +30.4% | ||
| 2003 | -$25.03M | +505.2% | ||
| 2002 | -$4.14M | — |
Net Income values are taken from Alnylam Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual net income for Alnylam Pharmaceuticals (ALNY) came in at $313.75M – plunged 212.8% year-over-year.
$313.75M stands as the all-time-high annual net income, posted in 2025, against a low of -$1.13B during 2022.
Within Healthcare, Alnylam Pharmaceuticals (ALNY) ranks 9th among 8 peers we track. The peer median for net income is $15.15B.
Alnylam Pharmaceuticals Net Income by Year
Alnylam Pharmaceuticals Net Income 2025: $313.75M
Alnylam Pharmaceuticals net income in 2025 was $313.75M, plunged 212.8% below 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Net Income 2024: -$278.16M
Alnylam Pharmaceuticals net income in 2024 was -$278.16M, plunged 36.8% below 2023.
Alnylam Pharmaceuticals Net Income 2023: -$440.24M
Alnylam Pharmaceuticals net income in 2023 was -$440.24M, plunged 61.1% below 2022.
Alnylam Pharmaceuticals Net Income 2022: -$1.13B
Alnylam Pharmaceuticals net income in 2022 was -$1.13B, surged 32.6% from 2021. This figure represents the lowest annual value in the available history.
Alnylam Pharmaceuticals Net Income 2021: -$852.82M
Alnylam Pharmaceuticals net income in 2021 was -$852.82M.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers — Net Income
Companies in the same sector as Alnylam Pharmaceuticals, ranked by their latest net income.
| Company | Net Income | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $102.43B | Healthcare |
| Johnson & Johnson (JNJ) | $26.80B | Healthcare |
| Eli Lilly and Company (LLY) | $20.64B | Healthcare |
| Merck & Co., Inc. (MRK) | $18.25B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $12.06B | Healthcare |
| AstraZeneca PLC (AZN) | $10.26B | Healthcare |
| Amgen Inc. (AMGN) | $7.71B | Healthcare |
| AbbVie Inc. (ABBV) | $4.23B | Healthcare |
Frequently asked questions
What is Alnylam Pharmaceuticals's net income?
- Latest reported net income for Alnylam Pharmaceuticals (ALNY) is $313.75M (period ending December 31, 2025).
How has Alnylam Pharmaceuticals net income changed year-over-year?
- Alnylam Pharmaceuticals (ALNY) net income changed -212.8% year-over-year on the latest annual filing.
When did Alnylam Pharmaceuticals net income hit its highest annual value?
- Alnylam Pharmaceuticals net income reached its highest annual value of $313.75M in 2025.
What was Alnylam Pharmaceuticals net income in 2024?
- Alnylam Pharmaceuticals (ALNY) net income in 2024 was -$278.16M.
What was Alnylam Pharmaceuticals net income in 2025?
- Alnylam Pharmaceuticals (ALNY) net income in 2025 was $313.75M.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ALNY Overview
Company profile, financial tools, and key metrics
ALNY Revenue Counter
Earns $117.77 every second. See per minute, hour, and day.
ALNY Earnings Counter
Earns $9.95 per second net profit. See per minute, hour, and day.
ALNY Economic Scale
Exceeds Curacao's GDP. Compare with world economies.
ALNY What If Invested
What if you had invested $1,000? See historical returns from any date.
ALNY How It Makes Money
Discover visual breakdown of $3.71B in revenue — where it comes from and where it goes.
ALNY Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ALNY Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ALNY Daily Price Character
Explosive · 50.6% historical win rate (green days). Streaks & record days.
ALNY Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.